Current Studies

PREVAIL TA-8995-304 (New Amsterdam) 20604 (Bayer) Phase III January 2023-Present

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies. NCT05202509

OCEANIC AF 19767 (Bayer) Phase III       December 2022-Present

A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Prevention of Stroke or Systemic Embolism in Male and Female Participants Aged 18 Years and Older With Atrial Fibrillation at Risk for Stroke. NCT05643573

EVOLVE-MI 20190184 (Amgen) Phase IV October 2022-Present

A Pragmatic Randomized Multicenter Trial of evolocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction. NCT05284747

GARDEN-TIMI 74 C3651011 (Pfizer). Phase II September 2022-Present

A Phase 2, double blind, randomized, placebo-controlled, 4 arm study to investigate symptoms, function, health-related quality of life and safety with repeated subcutaneous administration of prosegromab versus placebo in adult participants with heart failure.  NCT05492500. **First Site to Enroll a Patient in the United States**

ACTIV-4A 92596943 (Matthew Neal, MD/NHLBI) Phase IV July 2022-Present

A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19. NCT04505774

CRD 740-201 (Cardurion) Phase II April 2022-Present

A Phase 2 randomized, double-blind, placebo-controlled, clinical study to assess the effectiveness of CRD 740 in subjects with chronic heart failure. NCT05409183. **First Site to Enroll a Patient in the United States**

LUX-Dx TRENDS 92596943 (Boston Scientific Corporation) March 2022-Present

Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System. NCT04790344

VICTORION-2 PREVENT CKJX839B12302 (Novartis)         Phase III January 2022-Present

A randomized, double blind, placebo-controlled multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease. NCT05030428

Global Prevalence of ATTR-CM in Participants with HFpEF B3461087 (Pfizer)       April 2021- Present 

This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved ejection fraction (HFpEF)]. NCT04424914

REALIZE-K D9480C00018 (AstraZeneca) Phase IV     February 2021- Present              

Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalemia in Patients with Symptomatic Heart Failure with Reduced Ejection Fraction and Receiving Spironolactone NCT04676646

FINEARTS-HF 20103 (Bayer)   Phase III  August 2020-Present            

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Finerenone (BAY 94-8862) on Morbidity and Mortality in Participants with Heart Failure and Left Ventricular Ejection Fraction >40%. NCT01874431